Stockreport

CHMP recommends RYBREVANT®? (amivantamab) in combination with LAZCLUZE®? (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer [Yahoo!...

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of disease progression or death by 30 percent versus osimertinib monotherapy BEE [Read more]